Arovella Therapeutics Limited (ALA.AX)
AUD 0.08
(0.0%)
AUD 0.08
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 13.28 Million AUD | 142.82% |
| 2023 | 5.47 Million AUD | -40.61% |
| 2022 | 9.21 Million AUD | -13.8% |
| 2021 | 10.68 Million AUD | 59.33% |
| 2020 | 6.7 Million AUD | -58.73% |
| 2019 | 16.25 Million AUD | -2.34% |
| 2018 | 16.64 Million AUD | -16.85% |
| 2017 | 20.01 Million AUD | 2.56% |
| 2016 | 19.51 Million AUD | -14.48% |
| 2015 | 22.82 Million AUD | 12.16% |
| 2014 | 20.34 Million AUD | 89.65% |
| 2013 | 10.72 Million AUD | 9.99% |
| 2012 | 9.75 Million AUD | -27.88% |
| 2011 | 13.52 Million AUD | 13.64% |
| 2010 | 11.9 Million AUD | -28.35% |
| 2009 | 16.61 Million AUD | 3.41% |
| 2008 | 16.06 Million AUD | -23.5% |
| 2007 | 20.99 Million AUD | 26.27% |
| 2006 | 16.62 Million AUD | 11.22% |
| 2005 | 14.95 Million AUD | -7.11% |
| 2004 | 16.09 Million AUD | 245.95% |
| 2003 | 4.65 Million AUD | 47.97% |
| 2002 | 3.14 Million AUD | -48.6% |
| 2001 | 6.11 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 13.28 Million AUD | 0.0% |
| 2024 Q2 | 5.32 Million AUD | 0.0% |
| 2024 FY | 13.28 Million AUD | 142.82% |
| 2024 Q3 | 13.28 Million AUD | 149.33% |
| 2024 Q1 | 5.32 Million AUD | -42.16% |
| 2023 Q2 | 5.86 Million AUD | 0.0% |
| 2023 Q3 | 5.47 Million AUD | -6.66% |
| 2023 Q4 | 9.21 Million AUD | 68.39% |
| 2023 FY | 5.47 Million AUD | -40.61% |
| 2023 Q1 | 5.86 Million AUD | -36.38% |
| 2022 Q1 | 8.42 Million AUD | -21.21% |
| 2022 FY | 9.21 Million AUD | -13.8% |
| 2022 Q4 | 9.21 Million AUD | 0.0% |
| 2022 Q3 | 9.21 Million AUD | 9.4% |
| 2022 Q2 | 8.42 Million AUD | 0.0% |
| 2021 Q1 | 10.41 Million AUD | 55.21% |
| 2021 Q4 | 10.68 Million AUD | 0.0% |
| 2021 Q3 | 10.68 Million AUD | 2.66% |
| 2021 FY | 10.68 Million AUD | 59.33% |
| 2021 Q2 | 10.41 Million AUD | 0.0% |
| 2020 Q2 | 8.1 Million AUD | 0.0% |
| 2020 Q3 | 6.7 Million AUD | -17.2% |
| 2020 FY | 6.7 Million AUD | -58.73% |
| 2020 Q4 | 6.7 Million AUD | 0.0% |
| 2020 Q1 | 8.1 Million AUD | -50.16% |
| 2019 Q3 | 16.25 Million AUD | -15.85% |
| 2019 Q2 | 19.31 Million AUD | 0.0% |
| 2019 FY | 16.25 Million AUD | -2.34% |
| 2019 Q1 | 19.31 Million AUD | 16.05% |
| 2019 Q4 | 16.25 Million AUD | 0.0% |
| 2018 Q1 | 18.28 Million AUD | -8.63% |
| 2018 Q2 | 18.28 Million AUD | 0.0% |
| 2018 Q4 | 16.64 Million AUD | 0.0% |
| 2018 Q3 | 16.64 Million AUD | -9.0% |
| 2018 FY | 16.64 Million AUD | -16.85% |
| 2017 Q3 | 20.01 Million AUD | 5.32% |
| 2017 FY | 20.01 Million AUD | 2.56% |
| 2017 Q4 | 20.01 Million AUD | 0.0% |
| 2017 Q2 | 19 Million AUD | 0.0% |
| 2017 Q1 | 19 Million AUD | -2.62% |
| 2016 Q4 | 19.51 Million AUD | 0.0% |
| 2016 Q1 | 20.12 Million AUD | -11.8% |
| 2016 Q3 | 19.51 Million AUD | -3.04% |
| 2016 Q2 | 20.12 Million AUD | 0.0% |
| 2016 FY | 19.51 Million AUD | -14.48% |
| 2015 Q2 | 19.26 Million AUD | 0.0% |
| 2015 FY | 22.82 Million AUD | 12.16% |
| 2015 Q4 | 22.82 Million AUD | 0.0% |
| 2015 Q3 | 22.82 Million AUD | 18.47% |
| 2015 Q1 | 19.26 Million AUD | -5.33% |
| 2014 FY | 20.34 Million AUD | 89.65% |
| 2014 Q2 | 21.32 Million AUD | 0.0% |
| 2014 Q3 | 20.34 Million AUD | -4.6% |
| 2014 Q1 | 21.32 Million AUD | 98.8% |
| 2014 Q4 | 20.34 Million AUD | 0.0% |
| 2013 Q2 | 10.15 Million AUD | 0.0% |
| 2013 Q3 | 10.72 Million AUD | 5.63% |
| 2013 Q4 | 10.72 Million AUD | 0.0% |
| 2013 FY | 10.72 Million AUD | 9.99% |
| 2013 Q1 | 10.15 Million AUD | 4.13% |
| 2012 Q4 | 9.75 Million AUD | 0.0% |
| 2012 FY | 9.75 Million AUD | -27.88% |
| 2011 FY | 13.52 Million AUD | 13.64% |
| 2011 Q4 | 13.52 Million AUD | 0.0% |
| 2010 FY | 11.9 Million AUD | -28.35% |
| 2010 Q4 | 11.9 Million AUD | 0.0% |
| 2009 FY | 16.61 Million AUD | 3.41% |
| 2009 Q4 | 16.61 Million AUD | 0.0% |
| 2008 Q4 | 16.06 Million AUD | 0.0% |
| 2008 FY | 16.06 Million AUD | -23.5% |
| 2007 Q4 | 20.99 Million AUD | 0.0% |
| 2007 FY | 20.99 Million AUD | 26.27% |
| 2006 FY | 16.62 Million AUD | 11.22% |
| 2006 Q4 | 16.62 Million AUD | 0.0% |
| 2005 FY | 14.95 Million AUD | -7.11% |
| 2005 Q4 | 14.95 Million AUD | 0.0% |
| 2004 FY | 16.09 Million AUD | 245.95% |
| 2004 Q4 | 16.09 Million AUD | 0.0% |
| 2003 Q4 | 4.65 Million AUD | 0.0% |
| 2003 FY | 4.65 Million AUD | 47.97% |
| 2002 FY | 3.14 Million AUD | -48.6% |
| 2001 FY | 6.11 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AdAlta Limited | 5.57 Million AUD | -138.376% |
| Acrux Limited | 8.96 Million AUD | -48.217% |
| Actinogen Medical Limited | 21.31 Million AUD | 37.665% |
| AnteoTech Limited | 9.38 Million AUD | -41.61% |
| Argenica Therapeutics Limited | 16.37 Million AUD | 18.885% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -694.813% |
| Alterity Therapeutics Limited | 19.22 Million AUD | 30.894% |
| Amplia Therapeutics Limited | 14.84 Million AUD | 10.511% |
| Avecho Biotechnology Limited | 7.31 Million AUD | -81.502% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -320.456% |
| Biome Australia Limited | 8.27 Million AUD | -60.505% |
| Biotron Limited | 493.47 Thousand AUD | -2592.063% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | 88.188% |
| BTC Health Limited | 5.14 Million AUD | -158.015% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | 13.019% |
| CSL Limited | 56.93 Billion AUD | 99.977% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 91.409% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 94.252% |
| Cynata Therapeutics Limited | 8.38 Million AUD | -58.372% |
| Dimerix Limited | 32.07 Million AUD | 58.587% |
| EZZ Life Science Holdings Limited | 25.55 Million AUD | 48.009% |
| Hexima Limited | 2.26 Million AUD | -485.485% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -418.028% |
| Immuron Limited | 15.54 Million AUD | 14.568% |
| Immutep Limited | 147.44 Million AUD | 90.99% |
| Imugene Limited | 151.39 Million AUD | 91.225% |
| Invex Therapeutics Ltd | 6.12 Million AUD | -117.068% |
| Memphasys Limited | 12.43 Million AUD | -6.875% |
| Nanollose Limited | 241.95 Thousand AUD | -5390.65% |
| Neuren Pharmaceuticals Limited | 247.97 Million AUD | 94.643% |
| Noxopharm Limited | 6.78 Million AUD | -95.831% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -144.389% |
| Nyrada Inc. | 5.9 Million AUD | -124.887% |
| Orthocell Limited | 26.61 Million AUD | 50.086% |
| PharmAust Limited | 11.12 Million AUD | -19.414% |
| Patrys Limited | 4.16 Million AUD | -219.222% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 51.499% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | -22.157% |
| Prescient Therapeutics Limited | 20.39 Million AUD | 34.856% |
| PYC Therapeutics Limited | 91.23 Million AUD | 85.44% |
| Race Oncology Limited | 20.22 Million AUD | 34.327% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | 81.558% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | -108.563% |
| Starpharma Holdings Limited | 36.81 Million AUD | 63.914% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 96.665% |
| Tissue Repair Ltd | 19.38 Million AUD | 31.485% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -156.292% |